Selatogrel is an investigational, potent, fast-acting, reversible, and highly selective P2Y12 inhibitor, being developed for the treatment of an acute myocardial infarction (AMI) in patients with a recent history of AMI. It is intended to be self-administered subcutaneously via a drug delivery system (autoinjector).
This novel, self-administered emergency agent has the potential to protect heart muscle in the very early phase of an AMI – in the crucial time between symptom onset and first medical attention – so as to treat the ongoing AMI and prevent early death.